Inhaled drugs are an important part of treatment for chronic lung disease, as the medicine rapidly reaches the airways.
Inhaled Antibiotics Therapy Market: Introduction
- Inhaled drugs are an important part of treatment for chronic lung disease, as the medicine rapidly reaches the airways. Metered-dose inhalers (MDIs), dry powder inhalers, nebulizers, and soft mist inhalers are currently available with different medicines for the treatment of respiratory diseases. Increase in R&D expenditure for the development of new therapies and promising drugs in pipeline and development of approaches for early diagnosis and treatment reducing undiagnosed cases boost the market.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78731
Key Drivers and Restraints of Global Inhaled Antibiotics Therapy Market
- Prevalence of respiratory diseases has increased globally, especially in the last decade. Asthma is a major health concern affecting a large number of people across the globe. Chronic obstructive pulmonary disease (COPD) is also a life-threatening lung disease that is responsible for early mortality and high death rates. Chronic Obstructive Pulmonary Disease (COPD) includes chronic bronchitis and emphysema. According to the World Health Organization, currently 235 million people worldwide are suffering from asthma and 338,000 deaths due to asthma were reported in 2015. As per American Lung Association (ALA), there may be as many as 24 million adults in the U.S. living with COPD, making it the third-leading cause of death in the U.S., following heart disease and cancer. Over 800,000 hospitalizations each year, in the U.S., are related to COPD. According to the Forum of International Respiratory Societies (FIRS), COPD affects more than 200 million people and is likely to be the third-leading cause of death in the world by 2030. As per CDC, number of visits to emergency departments with pneumonia as the primary diagnosis was 1.3 million in U.S. in 2017. The disease burden is increasing among adults and thereby, increasing the need for inhaled antibiotics therapy.
Request for Analysis of COVID-19 Impact on Inhaled Antibiotics Therapy Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=78731
- Product launch is also boosting the market. In October 2017, Polyphor, launched an inhaled form of the investigational antibiotic murepavadin (POL7080), which acts specifically against the bacterial strain Pseudomonas aeruginosa, which is a strain found in patients with several lung diseases, including cystic fibrosis- and non-cystic fibrosis-associated bronchiectasis. In June 2018, Lupin launched antibiotic Tobramycin inhalation solution in the U.S. market for the management of cystic fibrosis.
- However, side-effects associated with drug inhalation and unattainability of single effective inhaler may hamper the market. The most common side-effects reported with administration of aerosolized antibiotics include cough, wheezing, hemoptysis, and dyspnea with considerable variation by antibiotic. The preparation of inhaled tobramycin that was initially studied included a preservative that was irritating to the airway.
Pre book Inhaled Antibiotics Therapy Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=78731<ype=S
Metered dose inhaler is estimated to dominate the global inhaled antibiotics therapy market
- Based on product type, the global inhaled antibiotics therapy market can be divided into metered dose inhaler, dry powder formulation, and spray
- The metered dose inhaler segment accounted for a prominent share of the market, in terms of revenue, in 2019 as it is a traditional product. According to an article published by Proveris Scientific Corpora in ONdrugDelivery Magazine in 2018, pressurized metered dose inhalers (pMDIs) are currently a prominent segment, in terms of revenue, in the asthma and chronic obstructive pulmonary disease (COPD) drug delivery devices market. The segment is expected to maintain this position in 2020.
- As per an article published in the National Center for Biotechnology Information in 2019, most common device types sold in Europe in 2011 were pressurized metered-dose inhalers (pMDIs; 47.5%), followed by dry powder inhalers (DPIs; 39.5%).
Top of Form
Ask for Discount :
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=78731
Key Manufacturers Operating in Market
The global inhaled antibiotics therapy market was highly fragmented in 2019. Key manufacturers operating in the global market are:
- Gilead Sciences
- Aradigm
- Lupin Ltd
- Polyphor
- Insmed Incorporated
- Pharmaero
- Savara Pharmaceuticals
- Joincare Pharmaceutical Group
- Pharmaxis Ltd
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453